Bardoxolone Methyl in Type 2 Diabetes and Advanced Chronic Kidney Disease
Bardoxolone Methyl in Type 2 Diabetes and Advanced Chronic Kidney Disease
About this item
Full title
Author / Creator
Publisher
United States: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
United States: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
To the Editor:
The increased risk of heart failure and cardiovascular events that led to early termination of the BEACON (Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes Mellitus: the Occurrence of Renal Events) trial, reported by de Zeeuw et al. (Dec. 26 issue),
1
may not be due to direct effects...
Alternative Titles
Full title
Bardoxolone Methyl in Type 2 Diabetes and Advanced Chronic Kidney Disease
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_1522683107
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1522683107
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMc1400872
